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Amyotrophic lateral sclerosis (ALS) is an incurable neurodegener-
ative disease characterized by preferential motor neuron death.
Approximately 15% of ALS cases are familial, and mutations in the
fused in sarcoma (FUS) gene contribute to a subset of familial ALS
cases. FUS is a multifunctional protein participating in many RNA
metabolism pathways. ALS-linked mutations cause a liquid–liquid
phase separation of FUS protein in vitro, inducing the formation of
cytoplasmic granules and inclusions. However, it remains elusive
what other proteins are sequestered into the inclusions and how
such a process leads to neuronal dysfunction and degeneration. In
this study, we developed a protocol to isolate the dynamic mutant
FUS-positive cytoplasmic granules. Proteomic identification of the
protein composition and subsequent pathway analysis led us to
hypothesize that mutant FUS can interfere with protein transla-
tion. We demonstrated that the ALS mutations in FUS indeed sup-
pressed protein translation in N2a cells expressing mutant FUS and
fibroblast cells derived from FUS ALS cases. In addition, the
nonsense-mediated decay (NMD) pathway, which is closely related
to protein translation, was altered by mutant FUS. Specifically,
NMD-promoting factors UPF1 and UPF3b increased, whereas a
negative NMD regulator, UPF3a, decreased, leading to the disrup-
tion of NMD autoregulation and the hyperactivation of NMD. Al-
terations in NMD factors and elevated activity were also observed
in the fibroblast cells of FUS ALS cases. We conclude that mutant
FUS suppresses protein biosynthesis and disrupts NMD regulation,
both of which likely contribute to motor neuron death.
amyotrophic lateral sclerosis | fused in sarcoma | protein translation |
nonsense-mediated decay | RNA-protein granules
Amyotrophic lateral sclerosis (ALS) is a neurodegenerativedisease characterized by motor neuron death and progressive
muscle wasting and paralysis. Approximately 15% of ALS cases are
caused by inheritable genetic mutations, mostly in an autosomal
dominant fashion. Mutations in the fused in sarcoma (FUS) gene
were discovered to contribute to a subset of familial ALS (1, 2).
FUS is a DNA- and RNA-binding protein that is primarily lo-
calized to the nucleus, where it forms dynamic ribonucleoprotein
granules. In contrast, ALS-related mutant FUS accumulates in the
cytoplasm and forms stable ribonucleoprotein granules, which can
lead to inclusion bodies and potentially contribute to neurotoxicity
(3–5). FUS mutations have also been shown to impact many RNA
metabolic processes, including transcription (6–8), splicing (9–11),
mRNA transport (12), and stabilization (13), ultimately contributing
to neuronal dysfunction. Recent studies demonstrated that muta-
tions in FUS cause the liquid–liquid phase separation (LLPS) of
FUS protein and the formation of self-assembled hydrogels (14) or
liquid droplets in vitro (15, 16). It is noted that LLPS has also been
reported for other RNA metabolic proteins involved in ALS, in-
cluding TDP-43 (17), C9ORF72 dipeptide repeat (18), hnRNPA1
(17), and TIA1 (19). Thus, other cellular proteins are likely to be
included in granules during LLPS in living cells, but the identities of
such proteins remain to be determined.
This study started with testing the hypothesis that the iden-
tification of proteins associated with mutant FUS-dependent
cytoplasmic granules is likely to provide critical insights into the
toxic mechanism of mutant FUS. We developed a protocol to
capture the dynamic mutant FUS-positive granules (3, 4) by
membrane filtration and identified protein components by pro-
teomic approaches. The bioinformatics analysis of proteins identi-
fied in wild-type (WT) and mutant FUS granules revealed multiple
RNA metabolism pathways, among which protein translation and
mRNA surveillance appeared to be novel.
We thus hypothesize that mutant FUS plays a role in protein
translation. Two previous studies reported that ALS-linked FUS
mutations were recruited to ribonucleoprotein granules; thus, FUS
was speculated to be involved in protein translation (3, 20). How-
ever, protein translation was not measured in either study. Using
three independent assays, we found that mutant FUS indeed im-
paired protein translation and that the cytoplasmic inclusions of
mutant FUS were positive for stalled ribosomal complexes.
Mutations in FUS have been demonstrated to cause aberrant
splicing (21); however, the molecular mechanism by which cells
handle defective mRNA has not been explored in ALS.
Nonsense-mediated decay (NMD) is a major mRNA surveil-
lance system that is known to degrade defective mRNA and ∼3–
20% of all mRNAs (22). NMD and protein translation are in-
terrelated, as NMD utilizes the translocating ribosome as a
proofreading mechanism for sensing defective mRNAs (23–25).
We demonstrate that the phosphorylation level of a critical
NMD regulator UPF1 (24), the NMD complex assembly, and the
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UPF1-mRNA binding all increased in the presence of mutant
FUS, supporting that NMD is activated by mutant FUS. Addi-
tionally, two potent NMD-activating regulators [UPF1 and
UPF3b (24, 26, 27)] were up-regulated, while the negative NMD
regulator [UPF3a (28)] was down-regulated in skin fibroblast
cells derived from a cohort of patients with ALS with FUS mu-
tations compared with cells from control subjects, indicating
disruption of the autoregulation of NMD. The hyperactivation of
NMD was demonstrated using an NMD reporter assay in N2a
cells and measuring endogenous mRNAs in the fibroblast cells of
FUS ALS cases. Overall, the findings from this study thus pro-
vide an in-depth understanding of how RNA metabolism and
protein translation are impacted by mutations in FUS and pro-
duce insights into the disease-causing mechanism of the mutant
FUS subtype of ALS.
Results
Proteins Related to Translation and mRNA Surveillance Are Enriched
in Mutant FUS Inclusions. A more complete understanding of the
protein composition that makes up the inclusions characteristic
of mutant FUS-dependent ALS would provide a better un-
derstanding of the mechanism(s) driving the disease. To achieve
this, we adapted a membrane filtration assay that was originally
developed for detecting differentially soluble protein complexes
(29). Utilizing previously described conditions in which radio-
immunoprecipitation assay (RIPA) buffer was used to lyse cells
(30), none of the WT, R495X, P525L, or R521G mutant FUS
proteins were detected on the PVDF membrane (Fig. 1A). As a
positive control and negative control, respectively, A4V mutant
SOD1 was detected on the PVDF membrane filter, while WT
SOD1 was not. The results suggest that, unlike A4V mutant
SOD1-dependent cytoplasmic aggregates, mutant FUS cyto-
plasmic inclusions are dynamic and disassembled under the
experimental conditions.
A protocol using a hypotonic lysis buffer with a low detergent
concentration was developed (SI Appendix, Fig. S1A). Using these
conditions, P525L and R495X mutant FUS was detected on the
membrane filter along with A4V mutant SOD1, whereas less WT
FUS was detected and no WT SOD1 was detected (Fig. 1B).
Native gel electrophoresis (4) also confirmed that FUS protein
remained as an oligomeric species under these conditions,
whereas FUS protein prepared in the RIPA buffer migrated faster
(SI Appendix, Fig. S1B). We subjected the membrane “dots” to
trypsin digestion followed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) using a published protocol (30). A
total of 291, 268, and 278 proteins in FUS WT, R495X, and
P525L, respectively, met the protein identification criteria de-
scribed in SI Appendix and were considered significant identifi-
cations (Datasets S1–S3).
Proteins identified in the granules were subjected to functional
enrichment analysis using the integrative tool, Enrichr (31, 32).
The Gene Ontology (GO): Molecular Function database (33) and
the DISEASES database (34) were utilized for analyzing protein
functions and disease relevance, respectively. The top 20 most
significant molecular function annotations aggregated from the
GO: Molecular Function database by Enrichr revealed a variety of
RNA-binding functions associated with WT (Fig. 1C) and mutant
FUS (Fig. 1D). It is noted that several properties, including
translation factor activity, tRNA binding, and RNA cap binding,
are related to protein translation and mRNA surveillance mech-
anisms. The top 10 most significant results from the disease-gene
association analysis for WT and mutant FUS (SI Appendix, Fig.
S2) show a number of neurodegenerative diseases, including lat-
eral sclerosis and Charcot–Marie–Tooth disease. Interestingly, the
disease identified with a high significance was Diamond–Blackfan
anemia, a severe ribosomopathy that results in defective protein
synthesis (35). This association suggests that proteins identified in
FUS granules are likely to be involved in protein translation. We
therefore focused on testing the function of FUS in protein syn-
thesis and related mRNA surveillance pathways.
We next examined the subcellular localization of critical proteins
involved in protein translation (eIF3, eIF4A1, eIF4G, and rpS6)
and mRNA surveillance (eIF4A3) that were identified in the MS
results. In primary cortical neurons transfected with EGFP-tagged
FUS, eIF4A3 (Fig. 1E), eIF3 (Fig. 1F), eIF4A1, eIF4G, and rpS6
(SI Appendix, Fig. S3 A–C, respectively) were all colocalized with
cytoplasmic inclusions of mutant FUS. As a positive control, mu-
tant FUS inclusions in primary neurons were positive for the stress
granule marker G3BP1 (SI Appendix, Fig. S3D) as previously
reported (4). The immunoprecipitation (IP) results also demon-
strated that eIF3, eIF4G, and eIF4A3 interacted more with the
mutant than WT FUS (Fig. 1G), validating the proteomic and
colocalization results.
Protein Translation Is Impaired in the Presence of Mutant FUS. Based
on the above proteomic identifications, GO enrichment analysis,
and colocalization of translation machinery to the mutant FUS
inclusions, we set out to test whether protein translation is im-
paired by ALS mutants of FUS using three independent assays.
Utilizing a translation reporter assay (36), we examined how
mutant FUS changed cap-dependent protein translation.
Cotransfection of R495X or P525L mutant FUS with the reporter
construct resulted in 50% and 70% reductions in the translation of
the Renilla reporter gene, respectively (Fig. 2A). No detectable
change was observed in cells transfected with empty vector (EV)
or WT FUS. The control internal ribosomal entry site (IRES)-
dependent translation of the luciferase gene was not changed (Fig.
2A). The second assay using an in vitro 35S-methionine (35S-Met)
incorporation assay to measure translation of native mRNA
showed that 35S-Met incorporation decreased by 25% and 35%,
respectively, in the presence of mutant FUS compared with WT FUS
or the EV control (Fig. 2B). Third, to examine endogenous protein
translation, we used the surface sensing of translation (SUnSET)
assay in which puromycin was used as a structural analog of amino-
acyl tRNAs to prevent elongation after being incorporated into
the nascent polypeptide chain (37). N2a cells were transfected with
either EV,WT, or mutant FUS and treated with puromycin. Western
blot analysis using an antipuromycin antibody showed reduced
translation in cells expressing mutant FUS (Fig. 2 C and D).
Finally, we carried out the SUnSET assay to examine protein
translation in the skin fibroblast cells derived from patients with
familial ALS who were carrying R521G or P525R (38) FUS
mutations and from healthy controls with WT FUS (Fig. 2 E
and F). Protein translation decreased by ∼30% in fibroblast
cells from FUS ALS cases. The above results consistently
support that mutant FUS represses protein translation.
We next examined whether FUS inclusions contained pur-
omycinlated proteins. Immunofluorescence using the same anti-
puromycin antibody showed that puromycinlated proteins were
colocalized with mutant FUS inclusions (Fig. 2G), suggesting that
translation complexes are localized in mutant FUS inclusions.
Moreover, to test whether mRNA was also localized to the in-
clusion, we performed RNA fluorescence in situ hybridization
(FISH) with two different RNA probes in N2a cells expressing
WT or P525L mutant FUS. A generic Cy3 oligo d(T)21 probe was
used to test mature polyadenylated mRNAs (Fig. 2H). Mature
mRNA was distributed throughout the cytoplasm in cells with EV
orWT FUS. However, a significant accumulation of mRNA in the
mutant FUS inclusions was observed, which is consistent with
previous observations (39). FUS has been reported to regulate the
splicing of its own transcript (10); thus, we tested a probe specific
to FUS transcript (exon 4) and found that FUS mRNA was also
localized to the mutant FUS inclusions (SI Appendix, Fig. S3E).
The results support that mutant FUS inclusions were colocalized
with translation machinery and mature mRNAs.
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We next examined whether translation initiation is impaired by
mutant FUS. Binding of the initiation factor eIF4E to the 5′ cap
of mRNA is the rate-limiting step in translation initiation where
regulation often occurs (40). We performed a 7′-methylguanosine
(7′MG) pulldown as an in vitro cap-binding assay (41) in the
presence of WT or mutant FUS. After 7′MG pulldown, key
members of the preinitiation complex were observed (Fig. 2I).
Similar levels of eIF4G, eIF4E, and eIF4A1 were pulled down
regardless of the presence of WT or mutant FUS. Neither WT nor
mutant FUS bound to the 5′ cap. As a negative control,
eIF4A3 also did not bind to the 5′ cap. The results suggest that
mutant FUS does not interfere with the binding of the initiation
complex to the 5′ cap structure in the translation initiation stage.
Thus, it is likely that translation is disrupted by mutant FUS after
the initiation step, resulting in premature termination.
We hypothesized that prematurely terminated polypeptides
resulting from defective translation in the presence of mutant FUS
will be polyubiquitinated and targeted for degradation. Therefore,
we examined the level of K48-linked polyubiquitination in cells
expressing WT or mutant FUS, since it is the major signal for
targeting substrates for proteasomal degradation. Using an anti-
K48 polyubiquitination tandem ubiquitin-binding entity (42), we
Fig. 1. Proteomic identification, enrichment analysis, and validation of proteins in WT or mutant FUS inclusions isolated by membrane filtration. Membrane
filtration, followed by dot blotting of granules isolated using the RIPA buffer (A) or the low-detergent hypotonic lysis buffer (B), was performed. The mo-
lecular function of proteins identified in WT (C) or mutant (D) FUS inclusions was analyzed using Enrichr software with the GO: Molecular Functions database.
The top 20 most significant (P < 0.05) molecular functions are represented. Immunofluorescent staining of eIF4A3 (E) and eIF3 (F) in mouse primary cortical
neurons was performed. Arrows indicate inclusions where proteins of interest are colocalized. (Scale bars: regular view, 20 μm; zoomed-in views, 5 μm.) (G)
FUS IP, followed by Western blot for translation initiation factors (eIF4AIII, eIF3, and eIF4G) that were uniquely identified in mutant FUS inclusions.
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found that the K48 polyubiquitination level increased ∼1.5- to 1.8-
fold in cells expressing mutant FUS compared with WT FUS and
the EV control (Fig. 2 J and K). In contrast, the level of K63-linked
polyubiquitination, which is involved with other nonproteasome
processes, did not change with either WT or mutant FUS (SI Ap-
pendix, Fig. S4). These results collectively support that ALS muta-
tions in FUS cause defects in protein translation.
NMD Pathway Is Activated by Mutant FUS. Protein translation and
mRNA surveillance pathways are interrelated (23, 25). It has been
reported that the inhibition of protein translation elongation by
cycloheximide (43) can up-regulate NMD factors and activate
NMD (44). Thus, we set to examine whether mutations in FUS
can impact the mRNA degradative pathway NMD. UPF1 (24, 27)
and UPF3b (28) are two critical positive regulators of NMD, and
UPF1 phosphorylation (p-UPF1) is a critical step in NMD acti-
vation (24, 45). We evaluated the levels of UPF1, p-UPF1, and
UPF3b in the skin fibroblast cells derived from six FUS ALS cases
and five healthy controls (Fig. 3A). The antibody used for p-
UPF1 was an anti–phospho-Ser/Thr ATM/AMR substrate
(p-S/T) previously reported (46). Quantitative results show
that the protein level of UPF1 (Fig. 3B), p-UPF1 (Fig. 3C), and
UPF3b (Fig. 3D) increased in patients with ALS compared with
healthy controls by 25%, 70%, and 35%, respectively. Similarly, N2a
cells expressing P525L or R495Xmutant FUS had increased levels of
UPF1 and UPF3b (SI Appendix, Fig. S5) and p-UPF1 (SI Appendix,
Fig. S6A). The results provide initial evidence that NMD activation is
elevated in the presence of mutant FUS in the cells of patients with
ALS with mutations in FUS.
We next examined the subcellular localization of endogenous
NMD factors in primary cortical neurons transfected with WT or
mutant FUS. The colocalization of mutant FUS with UPF1 and p-
UPF1 was demonstrated using two different p-UPF1 antibodies:
the p-S/T antibody used in the Western blot analysis (Fig. 3E) and
a different antibody against phosphor-S1089 of UPF1 (47) (Fig.
3F). Two additional NMD factors, UPF3b (Fig. 3G) and XRN1
(SI Appendix, Fig. S7A), were also localized in cytoplasmic inclu-
sions of mutant FUS in primary neurons. SMG6 was not localized
in mutant FUS inclusions serving as a control (SI Appendix, Fig.
S7B). Similar results were obtained from N2a cells expressing WT
or mutant FUS. Cytoplasmic inclusions of FUS were positive for
UPF1 and p-UPF1, UPF3b, and XRN1 (SI Appendix, Fig. S6 A–
C). SMG6 and eRF3b showed little localization to mutant FUS
inclusions in N2a cells (SI Appendix, Fig. S6 D and E). The
colocalization of NMD factors in mutant FUS inclusions further
suggests that mutant FUS may impact the NMD pathway.
Since the assembly of key NMD factors with UPF1 is a critical
aspect of pathway activation (48, 49), we next examined the as-
sembly of NMD factors in the presence of WT or mutant FUS.
Endogenous UPF1 IP followed by Western blots for various NMD
factors is shown in Fig. 4A. Quantitative analysis showed that the
UPF1 interaction with p-UPF1, UPF3b, the endonuclease SMG6,
and FUS increased ∼1.5- to 2.0-fold, with statistical significance in
the presence of mutant FUS (Fig. 4B). In addition, the translation
termination factor eRF3b increased in the presence of mutant
FUS (Fig. 4B). Enhanced assembly of NMD factors is additional
evidence that NMD was activated by mutant FUS.
We also tested the interaction of core NMD factors with
mRNAs. We treated cells with bromouridine to label mRNAs,
immunoprecipitated the labeled RNA with anti-BrdU antibody
(50), and assessed NMD proteins by Western blot (Fig. 4C).
Fig. 2. Protein translation is impaired in the pres-
ence of mutant FUS. (A) Cap-dependent translation
assay using the luciferase reporter in N2a cells
expressing EV, WT, or mutant FUS. Blue and red bars
represent the luminescence of the Renilla cap-
dependent reporter and the Firefly luciferase trans-
fection control, respectively. (B) In vitro 35S-Met in-
corporation assay using rabbit reticulocyte lysate
mixed with N2a cell lysate containing EV, WT, or
mutant FUS. After 1 h of incubation, proteins were
precipitated and radioactivity was measured using a
scintillation counter. Counts were normalized to the
EV. (C and D) SUnSET assay measuring puromycin
incorporated into proteins during translation in N2a
cells expressing EV, WT, or mutant FUS. Western
blots of puromycinylated proteins, FUS, and actin
loading control are shown in C. Quantification in D
was performed using the intensity of puromyciny-
lated proteins in each lane to normalize against
actin and EV. (E and F) SUnSET assay measuring pu-
romycin incorporated into proteins during trans-
lation in fibroblast cells of patients with FUS ALS.
Western blots of puromycinylated proteins and a
GAPDH loading control are shown in E, and quanti-
fication results are shown in F. (G) Immunofluores-
cent staining of puromycinylated proteins in N2a
cells expressing EV or EGFP-tagged WT or mutant
FUS. Cells were incubated with puromycin for
30 min, fixed using paraformaldehyde (PFA), and
stained with the antipuromycin antibody. (Scale
bars: 20 μm.) (H) RNA FISH using a Cy3-tagged 21-
mer oligo d(T) probe in N2a cells expressing WT or
mutant FUS. (Scale bars: 20 μm.) (I) 7′MG pulldown to
assess the cap binding and protein translation initiation in N2a cell lysate containing WT or mutant FUS. Various initiation complex members (eIF4E, eIF4G,
and eIF4AI), FUS, and a negative control (eIF4AIII) were blotted. (J) K48 polyubiquitination in N2a cells expressing EV, WT, or mutant FUS with FUS expression
and actin loading control. (K) Quantification of J using the K48 polyubiquitination intensity in each lane to normalize against actin and EV. Error bars in the
figure represent SDs for three biological replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA with a post hoc Tukey honest significant
difference test was used to determine P values for multiple pairwise comparisons in A, B, D, and K. A Student’s t test was used to determine P values for simple
pairwise comparison in F.
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Quantitative analysis showed that higher levels of NMD compo-
nents responsible for triggering NMD (eIF4A3 and UPF1) and
mRNA degradation (SMG6 and XRN1) were bound to RNAs in
the presence of mutant FUS (Fig. 4D). An RNA-binding protein,
PABP1, was used as a loading control and showed similar loading
in all samples. The above results consistently support that the
NMD pathway was activated by mutant FUS.
NMD Factors Are Dysregulated in Fibroblasts in FUS ALS Cases. We
demonstrated earlier that two positive regulators of NMD
(UPF1 and UPF3b) and UPF1 phosphorylation increased in the
skin fibroblast cells derived from six FUS ALS cases compared
with five healthy controls (Fig. 3 A–D). The NMD pathway is
tightly regulated by multiple mechanisms, including the molec-
ular brake UPF3a (28). UPF3a competitively blocks the in-
teraction of UPF3b with UPF2, thus delaying the activation of
NMD. We examined protein levels of UPF3a in six FUS ALS
cases (Fig. 5A) and found ∼30% lower levels of UPF3a protein
in the fibroblast cells from these patients (Fig. 5B). Similarly,
UPF3a protein levels decreased in N2a cells overexpressing the
R495X and P525L mutants (SI Appendix, Fig. S8 A and B).
We further examined how the mRNA levels of UPF1, UPF3b,
and UPF3a changed in the FUS ALS cases. The qPCR results
show elevated levels of UPF1 (Fig. 5C) and UPF3b (Fig. 5D) and
decreased levels of UPF3a (Fig. 5E) in the fibroblast cells of
FUS ALS cases. Similar results were obtained for mRNA levels
of these factors in N2a cells expressing WT or mutant FUS (SI
Appendix, Figs. S5 C and D and S8C). Consistent changes in both
mRNA and protein levels of the pro-NMD factors (UPF1 and
UPF3b) and the negative regulator (UPF3a) illustrate a pattern
of NMD dysregulation in the mutant FUS-linked familial pa-
tients with ALS, which will contribute to NMD hyperactivation.
UPF1-Mediated Autoregulation of NMD Is Impaired in FUS ALS Cases.
Core NMD factors, including UPF1 and UPF3b, are regulated
through an intricate autoregulatory mechanism, by which their own
mRNAs are targeted for NMD (44, 51). Given the dysregulation of
NMD factors as shown above, we hypothesized that the ALS mu-
tations in FUS disrupt the autoregulatory mechanism of NMD. To
test this hypothesis, we first performed endogenous UPF1 IP fol-
lowed by qPCR to examine whether the UPF1 protein binds its own
mRNA and UPF3b mRNA. Using normal goat serum as a control,
Fig. 3. Up-regulation of pro-NMD factors in cells of
patients with familial ALS and in primary neurons
expressing mutant FUS. (A–D) Levels of pro-NMD
factors in patients with ALS carrying the R521G or
P525R mutation and in control subjects with WT FUS.
Western blots of UPF1, p-UPF1, UPF3b, and actin
control were performed (A), and quantification of
UPF1 (B), p-UPF1 (C), and UPF3b (D) was normalized
against actin and obtained from three replicates.
Error bars represent the SD between individuals.
Quantifications were compared with healthy con-
trols using a Student’s t test. *P ≤ 0.05; **P ≤ 0.005.
(E–G) Immunofluorescent staining of UPF1, p-UPF1,
and UPF3b in mouse primary neurons transfected
with EV, EGFP-tagged WT, or mutant FUS at day 4 of
in vitro culture. (E) Immunofluorescent staining of
UPF1 and p-UPF1 using an anti–p-S/T ATM/AMR
substrate antibody. (F) Immunofluorescent staining
of p-UPF1 using an antibody against phosphor-
S1089 in UPF1. (G) Immunofluorescent staining of
UPF3b. Arrows indicate inclusions where proteins of
interest are colocalized. (Scale bars: regular views,
20 μm; zoomed-in views, 5 μm.)
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UPF1 protein was specifically pulled down by a UPF1 antibody
(Fig. 6A). Along with the UPF1 protein, UPF1 mRNA (Fig. 6B)
and UPF3b mRNA (Fig. 6C) were also pulled down. We then
overexpressed WT, P525L, or R495X mutant FUS in N2a cells and
performed a similar RNA IP experiment (Fig. 6 D–F). Quantitative
analysis showed that, consistent with earlier results (Fig. 4A), higher
levels of mutant FUS were pulled down with the UPF1 protein
(Fig. 6D). More importantly, lower levels of UPF1 mRNA (Fig. 6E)
and UPF3b mRNA (Fig. 6F) were pulled down along with the
UPF1 protein in the presence of mutant FUS, suggesting that
mutant FUS led to a lower turnover of UPF1 and UPF3b mRNA
by NMD. The dampened autoregulatory mechanism through UPF1
binding supports the observation of increases in the mRNA and
protein levels of UPF1 and UPF3b.
To further examine how decay is influenced by FUS mutations,
we measured the UPF1, UPF3b, and UPF3a mRNA levels by
qPCR after treating N2a cells expressing WT, P525L, or R495X
mutant FUS with the transcriptional inhibitor actinomycin D. In
cells expressing mutant FUS, the decay of UPF1 (Fig. 6G) and
UPF3b (Fig. 6H) mRNA was significantly slower than in controls.
In contrast, the mRNA decay of the NMD negative regulator
UPF3a was significantly faster in cells expressing mutant FUS (Fig.
6I). The results collectively support that the stability of NMD factor
mRNA was dysregulated by mutant FUS in a UPF1-dependent
manner (i.e., the NMD autoregulatory circuit is impaired).
Enhanced Decay of NMD Substrates in the Presence of ALS Mutant
FUS. Based on the above findings on the dysregulation of NMD
factors, we next tested whether the NMD activity is hyper-
activated using four well-characterized NMD reporters [β-globin
and GPX-1 with and without a premature stop codon (PTC)]
(52), as well as a cohort of documented endogenous NMD
substrates (53, 54). The levels of all four reporter transcripts
(WT β-globin, WT GPX-1, PTC β-globin, and PTC GPX-1) were
consistently lower in N2a cells expressing mutant FUS than in
cells expressing WT FUS (SI Appendix, Fig. S9). It is noted that
the transcript levels in WT FUS-expressing cells were unchanged
compared with the EV control, with the exception of PTC GPX-
1 (SI Appendix, Fig. S9D). The NMD reporter assays support
higher NMD turnover of normal and PTC-containing mRNAs in
the presence of mutant FUS.
To better characterize NMD activity, we measured the mRNA
levels of three NMD substrates: ATF3, ATF4, and TBL2 (53,
54). Total mRNA levels of ATF3, ATF4, and TBL2 (Fig. 7 A–C)
decreased in N2a cells expressing R495X or P525L mutant FUS
compared with cells expressing EV and WT FUS. As a control,
mRNA levels of cyclophilin D did not change (Fig. 7D). We next
measured the time course of mRNA levels after transcription
inhibition by actinomycin D. The mRNA decay of ATF3, ATF4,
and TBL2 (Fig. 7 E–G) was significantly faster in cells expressing
R495X or P525L mutant FUS compared with cells expressing
WT FUS. As a control, the decay of cyclophilin D did not differ
between cells expressing mutant and WT FUS (Fig. 7H). Fur-
thermore, we examined whether higher levels of these mRNAs
were associated with UPF1. UPF1 protein IP was performed
followed by qPCR to measure the amount of UPF1-bound
mRNAs. While similar levels of UPF1 protein were immunopre-
cipitated (Fig. 7I), higher levels of ATF3, ATF4, and TBL2
mRNAs were bound to UPF1 in the presence of mutant FUS (Fig.
7 J–L). All three lines of evidence support the enhanced NMD
decay of these endogenous substrates in cells expressing
mutant FUS.
We next examined the mRNA levels of ATF3, ATF4, and
TBL2 in fibroblast cells derived from patients with familial ALS.
Indeed, the levels of all three mRNAs were lower in cells of
patients with ALS than in healthy controls with WT FUS (Fig. 7
M–O). The results suggest that the NMD activity is induced in
clinically relevant samples.
Fig. 4. Interaction of NMD factors with UPF1 and RNAs increased in the
presence of mutant FUS. (A and B) NMD factors coprecipitated with en-
dogenous UPF1 from N2a cells expressing EV, WT, or mutant FUS. Immu-
noblots of UPF1, p-UPF1, eRF3b, UPF3b, SMG6, and 3× FLAG-FUS are shown
in A, and quantitative results are shown in B. Protein intensities were nor-
malized to corresponding UPF1 bands and compared with EV. (C and D)
NMD factors coprecipitated with BrdU-containing RNAs. N2a cells expressing
EV, WT, or mutant FUS were incubated with 1 μM BrdU, and RNAs were UV
cross-linked to proteins. BrdU IP was performed using an anti-BrdU antibody,
followed by Western blots for UPF1, eIF4A3, XRN1, SMG6, FUS, PABP1, and
actin. BrU, bromouridine. Quantification of proteins in C is shown in D.
Proteins were normalized to the loading control, PABP1, and compared with
EV. The purple, green, blue, and red bars represent EV, WT FUS, R495X FUS,
and P525L FUS, respectively. Error bars represent SDs for three biological
replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. Quantifications were com-
pared with EV using a Student’s t test.
Fig. 5. Down-regulation of the NMD negative regulator UPF3a in cells of
patients with familial ALS. (A and B) Protein levels of the NMD negative
regulator UPF3a in six patients with ALS and five control subjects, as shown
in Fig. 3 A and B. Western blots of UPF3a and an actin control (A) and
quantification of UPF3a normalized against actin (B) are shown. (C–E)
Quantification of mRNA levels of dysregulated NMD factors. qPCR of UPF1
(C), UPF3b (D), and UPF3a (E) was performed using the cycle threshold
method and is presented as the fold change in patients with ALS versus
controls. Actin was used to normalize cycle threshold values. Error bars
represent the SD between individuals. *P ≤ 0.05; **P ≤ 0.005. Quantifica-
tions were compared with healthy controls using a Student’s t test.
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Discussion
FUS (14–16) and other proteins implicated in ALS (17–19, 55)
have been reported to undergo LLPS and form liquid droplets,
which facilitates the formation of membrane-less RNA-protein
granules and inclusions (3–5). This study started with developing
a method to isolate dynamic FUS-containing granules and iden-
tifying their protein compositions. Enrichment analysis of identi-
fied proteins implied that both WT and mutant FUS are involved
in protein translation and mRNA surveillance (Fig. 1 C and D and
SI Appendix, Fig. S2). Tight spatiotemporal regulation of protein
synthesis in a motor neuron is critical for its function and survival
(56), and reduced protein synthesis can be detrimental to normal
neuronal function (57, 58). Moreover, mRNA surveillance is in-
timately integrated into protein translation (23). For instance,
eIF4A3 is a core exon junction complex member that aids in
initiating NMD (49). eIF3 is classically known as a critical initia-
tion factor; however, it is also required for efficient translation
termination in the event of NMD and promotes ribosomal recy-
cling (59, 60). However, it is unknown how defects in mRNA
surveillance are linked to suppression of protein synthesis by ALS
mutation in FUS. The colocalization of eIF4A3 and eIF3 in
mutant FUS inclusions (Fig. 1 E and F) led us to probe how
protein translation and NMD are altered by mutant FUS and to
discover the underlying mechanisms.
We used three independent assays to provide direct evidence
that mutant FUS negatively impacted global protein production
(Fig. 2 A–D). Furthermore, the SUnSET assay also detected sig-
nificant reduction of protein translation in fibroblast cells derived
from patients with familial ALS with two different FUS mutations
(Fig. 2 E and F). In addition, mutant FUS inclusions were colo-
calized with mRNAs (Fig. 2H) and puromycinylated peptides (Fig.
2G), suggesting that such inclusions are sites of defective protein
synthesis with stalled translation complexes. Mutant FUS inclu-
sions have been reported as stress granule-like with stress granule
markers such as G3BP1 and TIA1, but they display altered dy-
namics compared with heathy cells with endogenous WT FUS
(61–64). We suggest that the impairment of protein translation as
shown in this study is a functional consequence of the sequestra-
tion of the translation machinery in mutant FUS inclusions.
The above results raised the question how mRNAs resulting
from impaired translation would be handled. It was reported that
suppression of translation using cycloheximide up-regulated pro-
teins involved in the NMD pathway, particularly UPF1 and UPF3b
(44). Our proteomic analysis also suggested that proteins involved
in the mRNA surveillance pathway were enriched in mutant FUS
inclusions. We observed increased pro-NMD proteins UPF1 and
UPF3b in fibroblast cells derived from a cohort of patients with
familial ALS bearing two different FUS mutations, R521G and
P525R (Fig. 3 A–D), as well as in N2a cells expressing mutant FUS
(SI Appendix, Fig. S5). In addition, UPF1 phosphorylation (Fig. 3
E and F), NMD complex assembly (Fig. 4 A and B), and UPF1-
mRNA binding (Fig. 4 C and D) all increased in the presence of
mutant FUS, suggesting an elevated level of NMD activity as we
demonstrated with an NMD reporter assay (SI Appendix, Fig. S9),
in three endogenous NMD substrates in N2a cells expressing
mutant FUS (Fig. 7 A–H), and in fibroblast cells from patients with
FUS ALS (Fig. 7 M–O). We rationalized that higher levels of core
NMD factors in mutant FUS inclusions would aid in the degra-
dation of RNAs associated with prematurely terminated trans-
lation complexes, thus playing a protective role in FUS ALS. A
yeast genetic screen identified that UPF1 rescued mutant FUS
toxicity in Saccharomyces cerevisiae (65), and follow-up studies
showed a similar protective effect of UPF1 overexpression in pri-
mary neurons (66) and TDP-43 rat models (67).
Different from UPF1 and UPF3b, UPF3a functions as a mo-
lecular brake by competing with UPF3b for interaction with
UPF2 and delaying activation of the pathway (28). To our sur-
prise, we found that both protein and mRNA levels of UPF3a
decreased in the same cells of patients with familial ALS with
mutations in FUS (Fig. 5). Loss of the down-regulatory mecha-
nism could result in aberrant activation of NMD. Moreover,
NMD is regulated by an intricate autoregulatory circuit to pre-
vent overt activation of NMD. Specifically, the mRNA levels of
NMD factors UPF1 and UPF3b are degraded through the NMD
pathway itself (44, 51). Our results from mRNA decay experi-
ments demonstrate the stabilization of the pro-NMD factors
UPF1 and UPF3b and an increased degradation of the negative
regulator UPF3a (Fig. 6 G–I), suggesting a disruption in the
Fig. 6. Disruption in the NMD autoregulation loop. Endogenous UPF1 IP from N2a cells was performed, followed by Western blot (A) and qPCR mea-
surement of UPF1 (B) and UPF3b (C) mRNAs. N2a cell lysate was subjected to IP using normal goat serum (NGS) or goat anti-UPF1 antibody. The IP samples
were aliquoted for Western blot (A) and qPCR quantification (B and C) comparing RNA coprecipitated with UPF1 protein versus NGS control. UPF1 IP from N2a
cells expressing EV, WT, or mutant FUS was performed, followed by Western blot (D) and qPCR measurement of UPF1 (E) and UPF3b (F) mRNAs. UPF1, FUS,
and GAPDH were assessed by Western blot, as shown in D. qPCR quantification was normalized to UPF1 protein precipitated and presented as fold change
compared with EV. Turnover rates of UPF1 (G), UPF3b (H), and UPF3a (I) mRNAs in N2a cells expressing EV, WT, or mutant FUS are shown. Actinomycin D or
DMSO control was added 2 or 4 h before harvesting for RNA isolation. Individual mRNAs of interest were quantified by qPCR, normalized against RPL13a, and
presented as fold change versus DMSO treatment over time. Error bars represent the SD from three replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not
significant. ANOVA with a post hoc Tukey honest significant difference test was used in E–I, and a Student’s t test was used in B and C.
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autoregulatory circuit. These results consistently support a model
(Fig. 8) in which the NMD pathway is dysregulated and hyper-
activated in the presence of mutant FUS. It was reported that
UPF1 overexpression could increase the available pool of UPF1 to
reactivate the autoregulatory feedback (51), thus enabling the
degradation of UPF1 and UPF3b mRNAs and dampening the
hyperactivation of NMD. This mechanism can provide an expla-
nation of the reported protective effect of UPF1 overexpression in
TDP-43 and FUS ALS models (65–67).
Dysregulation of NMD factors can, in turn, contribute to
suppressing protein translation. For instance, besides its function
of promoting NMD, UPF3b was reported to recruit termination
factor eRFs to stalled ribosomes and to terminate protein
translation (68). Interestingly, mutations in UPF3b can result in
intellectual disabilities, autism spectrum disorder, and schizo-
phrenia. These disorders are likely the consequence of defective
NMD in dendrites and neurons, which results in deficient neu-
ronal maturation and dendritic branching (69, 70).
In mutant FUS ALS, translation suppression and subsequent
NMD activation appear to constitute a vicious cycle, as illus-
trated in Fig. 8. Increased translation termination events, po-
tentially due to increased binding of mutant FUS to mRNAs,
activate NMD at higher levels. Furthermore, the autoregulation
of NMD is disrupted as the pro-NMD factors UPF1 and UPF3b
increase and the molecular brake UPF3a decreases, contributing
to the hyperactivation of NMD and increased degradation of
natural NMD targets, such as ATF3, ATF4, and TBL2. This
hyperactivity resulting from defects in translation termination
may contribute to toxicity in motor neurons (Fig. 8). It is noted
that critical steps in this model, including suppressed protein
translation (Fig. 2 E and F); increased levels of UPF1, p-UPF1,
and UPF3b protein (Fig. 3 A–D) and mRNA (Fig. 5 C and D);
decreased levels of UPF3a protein (Fig. 5 A and B) and mRNA
(Fig. 5E); and increased NMD degradation of ATF3, ATF4, and
TBL2 mRNAs (Fig. 7 M–O), were consistently supported by
results from fibroblast cells derived from patients with familial
ALS carrying two different FUS mutations.
Although this study only demonstrated that mutant FUS sup-
pressed global protein translation, it is conceivable that local
translation in dendrites and axon terminals may also be impaired
by mutant FUS. FUS has been demonstrated to be part of RNA
transport granules and to be recruited to activated synapses (20,
71, 72). In cells bearing FUS mutations, however, there are defects
in synaptic morphology and function (58, 71–75). Decreases in
proteins required for synaptic maintenance and function may
contribute to an ALS phenotype. Additionally, overactivation of
NMD may produce deleterious effects in stress response path-
ways, including how cells respond to misfolded proteins, hypoxia,
and DNA damage (22, 44). NMD also functions in fine-tuning the
immune response by degrading mRNAs of proinflammatory fac-
tors (76). As neuroinflammation plays a role in ALS in a non–cell-
autonomous fashion (77, 78), it is conceivable that dysregulation
Fig. 7. Enhanced NMD activity in the presence of
mutant FUS. The mRNA levels of ATF3 (A), ATF4 (B),
TBL2 (C), and cyclophilin D (D) in N2a cells trans-
fected with EV, WT, or mutant FUS were de-
termined. The levels of the indicated mRNA were
quantified by qPCR using the cycle threshold (ΔΔCT)
method, and the fold changes compared with WT
are presented. Turnover rate of ATF3 (E), ATF4 (F),
TBL2 (G), and cyclophilin D (H) mRNAs in N2a cells
expressing EV, WT, or mutant FUS after treatment
with actinomycin or DMSO control. Individual
mRNAs of interest were quantified by qPCR, nor-
malized against RPL13a, and presented as fold
change versus DMSO treatment over time. Error bars
represent the SD from three replicates. (I–L) Amount
of ATF3, ATF4, and TBL2 mRNA bound to the
UPF1 protein. N2a cells were cotransfected with EV,
WT, or mutant FUS and an NMD reporter as in-
dicated. After UPF IP, Western blot (I) demonstrates
levels of UPF1 in lysate and IP samples. The levels of
ATF3 (J), ATF4 (K), and TBL2 (L) mRNA in the UPF1 IP
samples were quantified by qPCR using the ΔCT
method. The fold changes normalized to WT are
presented from three replicates. The mRNA levels of
ATF3 (M), ATF4 (N), and TBL2 (O) in fibroblast cells
derived from patients with familial ALS carrying FUS
mutations and healthy WT controls are shown. *P ≤
0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant.
ANOVA with a post hoc Tukey honest significant
difference test was used to determine P values in A–
L. A Student’s t test was used to determine P values
in M–O.
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of NMD in astrocytes and microglia may also impact the immune
response and contribute to the ALS phenotypes.
In summary, the mechanistic insights gained from this study begin
to describe the role of FUS in protein translation and a critical
mRNA quality control pathway, both of which are required for
neuronal maintenance and function. Sequestration of UPF1 in
mutant FUS inclusions, decrease in protein synthesis, NMD hyper-
activation, or a combination of these events likely plays a role in
neurodegeneration in ALS. It is noted that suppressed protein
translation (Fig. 2 E and F), NMD activation (Fig. 3 A–D), disrupted
NMD autoregulation (Fig. 5), and hyperactivity of NMD (Fig. 7 M–
O) were consistently demonstrated in the fibroblast cells of patients
with ALS with mutations in FUS. These mechanistic understandings
support the notion that regulation of NMD and protein translation
can serve as potential therapeutic targets for future development
of new ALS treatment. The results also have a broader impact,
since other RNA-binding proteins all undergo LLPS and form
cytoplasmic granules, including TDP-43, C9ORF72 dipeptide
repeat, hnRNPA1, and TIA1 (17–19, 55). Future studies will in-
vestigate whether these proteins, which are implicated in ALS,
frontotemporal dementia, and related disorders, also influence the
mRNA quality control pathway and impair protein translation.
Materials and Methods
Reagents, plasmids, oligonucleotide primers, and general methods for cell culture
and transfection, primary neuron isolation and culture, skin fibroblast cell culture
of patients with ALS, immunostaining, membrane filtration assay, LC-MS/MS,
proteomics and protein functional enrichment analysis, IP, real-time RT-PCR,
RNA FISH and confocal microscopy are described in SI Appendix, Materials and
Methods. Critical protocols are briefly described below, and more details can be
found in SI Appendix,Materials and Methods. Data are presented as means from
three independent experiments. ANOVAwith a post hoc Tukey honest significant
difference test was used to determine P values for multiple pairwise comparisons.
Patient Skin Fibroblast Culture. Human skin fibroblasts were prepared and
maintained as previously described (38). Informed consent was obtained
from all participants who donated a skin biopsy. Information on the
11 subjects (five patients with familial ALS with the R521G mutation, one
patient with the P525R mutation, and five healthy controls with WT FUS) is
shown in SI Appendix, Materials and Methods. The study was approved by
the Institutional Review Board of the University of Kentucky. Details on the
fibroblast cell culture are provided in SI Appendix, Materials and Methods.
Protein Translation Assays. Protein translation efficiency was measured using
three different assays: a cap-dependent translation reporter assay as pre-
viously described (36), an 35S-Met incorporation assay, and the SUnSET assay
as previously described (37). The SUnSET assay uses puromycin as a structural
analog of aminoacyl tRNAs to prevents elongation after being incorporated
into the nascent polypeptide chain. Details on all three assays are provided
in SI Appendix, Materials and Methods.
NMD Activity Assays. NMD activity was assessed using an NMD reporter assay
as previously described (52) or the qPCR of mRNA levels of endogenous NMD
substrates (53, 54). Details are provided in SI Appendix, Materials
and Methods.
Note Added in Proof. During the production of this article, one group
reported that FUS mutations suppress intraaxonal protein synthesis (79).
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